Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II

Cardiovascular Research

Volumn 105, Issue 3, 2015, Pages 304-317

  He, Zuowen ^a   Zhang, Xu ^b   Chen, Chen ^a   Wen, Zheng ^a   Hoopes, Samantha L ^c   Zeldin, Darryl C ^c   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cardiac hypertrophy; Cardiac remodelling; CYP2J2; Epoxyeicosatrienoic acids; Oxidative stress

Indexed keywords

11,12 EPOXYICOSATRIENOIC ACID; 2 CHLORO 5 NITROBENZANILIDE; ANGIOTENSIN II; ANTIFIBROTIC AGENT; ANTIOXIDANT; CARDIOVASCULAR AGENT; COLLAGEN TYPE 1; CYTOCHROME P450 2J2; EPOXYICOSATRIENOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTECTIVE AGENT; SMAD PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 11,12-EPOXY-5,8,14-EICOSATRIENOIC ACID; ARACHIDONATE EPOXYGENASE; CYTOCHROME P450; DIHOMO GAMMA LINOLENIC ACID; RELA PROTEIN, MOUSE; RELA PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIAC REMODELLING; CONTROLLED STUDY; DRUG EFFICACY; GENE OVEREXPRESSION; HEART DISEASE; HEART FIBROBLAST; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COCULTURE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RAT; TRANSGENIC MOUSE;

8,11,14-EICOSATRIENOIC ACID; ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PPAR GAMMA; RATS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84942099244     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv018     Document Type: Article

References (43)

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-582.
2. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C, Bergmann MW. Requirement of nuclear factor-kappaB in angiotensin II- And isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005;111: 2319-2325.
3. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241-248.
4. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano PJ, Singh K, Sawyer DB, Colucci WS. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 1999; 85:147-153.
5. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D.NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005;97:900-907.
6. Tsai CT, Tseng CD, Hwang JJ, Wu CK, Yu CC, Wang YC, Chen WP, Lai LP, Chiang FT, Lin JL. Tachycardia of atrial myocytes induces collagen expression in atrial fibroblasts through transforming growth factor beta1. Cardiovasc Res 2011;89:805-815.
7. Yeh YH, Kuo CT, Chan TH, Chang GJ, Qi XY, Tsai F, Nattel S, Chen WJ. Transforming growth factor-beta and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes. Cardiovasc Res 2011;91:62-70.
8. LinW, Wu G, Li S, Weinberg EM, Kumthip K, Peng LF, Mendez-Navarro J, Chen WC, Jilg N, Zhao H, Goto K, Zhang L, Brockman MA, Schuppan D, Chung RT. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem 2011;286:2665-2674.
9. MaB, Xiong X, Chen C, Li H, Xu X, Li X, Li R, Chen G, DackorRT, Zeldin DC, Wang DW. Cardiac-specific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice. Endocrinology 2013;154:2843-2856.
10. Zhao G, Wang J, Xu X, Jing Y, Tu L, Li X, Chen C, Cianflone K, Wang P, Dackor RT, Zeldin DC, Wang DW. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-alpha-induced injury. J Lipid Res 2012;53:456-466.
11. Seubert J, Yang B, Bradbury JA, Graves J, DeGraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, Rockman HA, Hammock BD, Murphy E, Zeldin DC. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATPsensitive K+ channels and p42/p44 MAPK pathway. Circ Res 2004;95:506-514.
12. Zhang Y, El-Sikhry H, Chaudhary KR, Batchu SN, Shayeganpour A, Jukar TO, Bradbury JA, Graves JP, DeGraff LM, Myers P, Rouse DC, Foley J, Nyska A, Zeldin DC, Seubert JM. Overexpression of CYP2J2 provides protection against doxorubicininduced cardiotoxicity. Am J Physiol Heart Circ Physiol 2009;297:H37-H46.
13. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001;276: 36059-36062.
14. Xu X, Zhang XA, Wang DW. The roles ofCYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 2011; 63:597-609.
15. Pathak M, Sarkar S, Vellaichamy E, Sen S. Role of myocytes in myocardial collagen production. Hypertension 2001;37:833-840.
16. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY. The antiinflammatory effect of laminar flow: The role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 2005;102:16747-16752.
17. Liu L, Chen C, GongW, Li Y, Edin ML, Zeldin DC, Wang DW. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther 2011;339:451-463.
18. Valente AJ, Clark RA, Siddesha JM, Siebenlist U, Chandrasekar B. CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18 expression, and Nox2- dependent cardiomyocyte hypertrophy. J Mol Cell Cardiol 2012;53:113-124.
19. Min LJ, Mogi M, Shudou M, Jing F, Tsukuda K, Ohshima K, Iwanami J, Horiuchi M. Peroxisome proliferator-activated receptor-gamma activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012;59:1079-1088.
20. Yayama K, Wang C, Chao L, Chao J. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998;31:1104-1110.
21. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 1997;96:2656-2666.
22. Askar SF, Bingen BO, Schalij MJ, Swildens J, Atsma DE, Schutte CI, de Vries AA, Zeppenfeld K, Ypey DL, Pijnappels DA. Similar arrhythmicity in hypertrophic and fibrotic cardiac cultures caused by distinct substrate-specific mechanisms. Cardiovasc Res 2013; 97:171-181.
23. Ma H, Gong H, Chen Z, Liang Y, Yuan J, ZhangG, Wu J, Ye Y, Yang C, Nakai A, Komuro I, Ge J, Zou Y. Association of Stat3 with HSF1 plays a critical role in G-CSF-induced cardioprotection against ischemia/reperfusion injury. J Mol Cell Cardiol 2012;52:1282-1290.
24. Shioura KM, Geenen DL, Goldspink PH. Assessment of cardiac function with the pressure-volume conductance system following myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2007;293:H2870-H2877.
25. Dolber PC, BaumanRP, Rembert JC, Greenfield JC Jr. Regional changes in myocyte structure in model of canine right atrial hypertrophy. Am J Physiol 1994;267:H1279-H1287.
26. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011;57:123-130.
27. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005;115:1221-1231.
28. Frantz S. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 2003;57:749-756.
29. Song C, Al-Mehdi AB, Fisher AB. Animmediate endothelial cell signaling response to lung ischemia. Am J Physiol Lung Cell Mol Physiol 2001;281:L993-L1000.
30. Li L, Li N, PangW, Zhang X, Hammock BD, Ai D, Zhu Y. Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis. PLoS ONE 2014;9:e94092.
31. Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X, Voltz JW, Zeldin DC, Wang DW. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 2010;334:784-794.
32. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003;42:737-743.
33. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005;288:C899-C905.
34. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG. Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000;403:103-108.
35. Buroker NE, Barboza J, Huang JY. The IkappaBalpha gene is a peroxisome proliferatoractivated receptor cardiac target gene. FEBS J 2009;276:3247-3255.
36. Chen F, Wang M, O'Connor JP, He M, Tripathi T, Harrison LE. Phosphorylation of PPAR-g via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kB. J Cell Biochem 2003;90:732-744.
37. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci USA 2006;103:7432-7437.
38. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-651.
39. Zhang L, Cheng J, Ma Y, Thomas W, Zhang J, Du J. Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: phosphorylation of p65 by IkappaB kinase and ribosomal kinase. Circ Res 2005;97:975-982.
40. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Antiinflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279.
41. Sarkar S, Vellaichamy E, Young D, Sen S. Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am J Physiol Heart Circ Physiol 2004;287:H107-H117.
42. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40:136-141.
43. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005;288:H461-H468.